KALA BIO Stock Surges 70% on AI Pivot, Eyes $180B Biotech Market
KALA BIO's shares skyrocketed 69.68% in pre-market trading after announcing its Researgency.ai platform launch in 14 days. The clinical-stage biotech company positions itself as the 'Palantir for biotech,' targeting AI's $180 billion healthcare opportunity.
Trading volume exploded to 51 million shares - 26x the 3-month average - as investors bet on the AI-powered transformation. The platform deploys autonomous agents for pharmaceutical workflows while maintaining traditional drug development pipelines.
This vertical AI play mirrors Palantir's government-tech success, now applied to life sciences. The market reaction suggests strong confidence in biotech's AI adoption curve, though the commercial execution remains unproven.